Sort by
Refine Your Search
-
Listed
-
Category
-
Employer
-
Field
-
from this research inform the development of new diagnostics, treatments, and vaccines against malaria, tuberculosis, schistosomiasis, Chagas and other neglected tropical diseases. Within the Parasite
-
100%, Zurich, fixed-term The research group for Chemical Biology and Molecular Imaging (Frei Research Group ) at ETH Zurich is looking for a doctoral researcher to develop chemistry inspired tools
-
aiming to improve the management of infected wounds. Our group is focused on: i) Developing novel fluorescent-based detection approaches for the continuous monitoring of wound healing. ii) Achieving
-
at Empa in Dübendorf drives innovations in joining technologies and corrosion management to enable evolution towards increasingly efficient, reliable and sustainable material technologies. Joining
-
general area of control & dynamical systems with application to mobility. Project background The candidate will work on the “Efficient Safe Train Dynamics” (ESTRA) project, in collaboration with Prof
-
on the development of state-of-the-art X-ray optics through the latest micro- and nanofabrication techniques. We are seeking a highly motivated PhD student to join our SNF-funded project, ABSOLUTE, under the guidance
-
. The acquired and already existing database will be used to further develop ML models for the automated detection of clinically relevant markers. The goal is to develop the technique towards potential clinical
-
interconnected systems in order to support sustainable urban development and the well-being of their inhabitants. Project background This dissertation is part of the National Research Programme 81 (NRP 81
-
bottom-up approach to robotics and develop soft materials and devices that would enable unusual form and unconventional functions for broader robotic applications. Project background Natural organisms
-
Chemistry with a relation to cancer research and immunobiology. The candidate will join our multi-disciplinary teams and focus on the development of novel modalities to target the PI3K-mTOR pathway